Prelude Therapeutics Incorporated
PRLD
$3.94
$0.102.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -18.79% | -13.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.79% | -13.23% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -18.79% | -13.23% | |||
| SG&A Expenses | 5.31% | -6.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.51% | -19.43% | |||
| Operating Income | 11.66% | 21.40% | |||
| Income Before Tax | 36.90% | 16.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 36.90% | 16.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.90% | 16.57% | |||
| EBIT | 11.66% | 21.40% | |||
| EBITDA | 11.80% | 21.82% | |||
| EPS Basic | 39.08% | 20.30% | |||
| Normalized Basic EPS | 33.75% | 26.62% | |||
| EPS Diluted | 37.05% | 20.30% | |||
| Normalized Diluted EPS | 33.75% | 26.62% | |||
| Average Basic Shares Outstanding | 3.52% | 4.70% | |||
| Average Diluted Shares Outstanding | 3.52% | 4.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||